Toxicity as prime selection criterion among SARS-active herbal medications

Publication type:
Journal article
Metadata:
Autoren
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000640107200019&DestLinkType=FullRecord&DestApp=WOS_CPL
DOI
10.1016/j.phymed.2021.153476
eISSN
1618-095X
Externe Identifier
  • Clarivate Analytics Document Solution ID: RN1IG
  • PubMed Identifier: 33593628
ISSN
0944-7113
Zeitschrift
PHYTOMEDICINE
Schlüsselwörter
  • COVID-19
  • Cytochrome P450, Phytochemicals
  • Rational phytotherapy
  • Public health
  • Toxicity
Artikelnummer
ARTN 153476
Datum der Veröffentlichung
2021
Status
Published
Titel
Toxicity as prime selection criterion among SARS-active herbal medications
Sub types
  • Review
Ausgabe der Zeitschrift
85

Data source: Web of Science (Lite)

Other metadata sources:
Autoren
DOI
10.1016/j.phymed.2021.153476
ISSN
0944-7113
Zeitschrift
Phytomedicine
Sprache
en
Artikelnummer
153476
Paginierung
153476 - 153476
Datum der Veröffentlichung
2021
Status
Published
Herausgeber
Elsevier BV
Herausgeber URL
http://dx.doi.org/10.1016/j.phymed.2021.153476
Datum der Datenerfassung
2023
Titel
Toxicity as prime selection criterion among SARS-active herbal medications
Ausgabe der Zeitschrift
85

Data source: Crossref

Abstract
We present here a new selection criterion for prioritizing research on efficacious drugs for the fight against COVID-19: the relative toxicity versus safety of herbal medications, which were effective against SARS in the 2002/2003 epidemic. We rank these medicines according to their toxicity versus safety as basis for preferential rapid research on their potential in the treatment of COVID-19. The data demonstrate that from toxicological information nothing speaks against immediate investigation on, followed by rapid implementation of Lonicera japonica, Morus alba, Forsythia suspensa, and Codonopsis spec. for treatment of COVID-19 patients. Glycyrrhiza spec. and Panax ginseng are ranked in second priority and ephedrine-free Herba Ephedrae extract in third priority (followed by several drugs in lower preferences). Rapid research on their efficacy in the therapy - as well as safety under the specific circumstances of COVID-19 - followed by equally rapid implementation will provide substantial advantages to Public Health including immediate availability, enlargement of medicinal possibilities, in cases where other means are not successful (non-responders), not tolerated (sensitive individuals) or just not available (as is presently the case) and thus minimize sufferings and save lives. Moreover, their moderate costs and convenient oral application are especially advantageous for underprivileged populations in developing countries.
Addresses
  • Institute of Toxicology, Johannes Gutenberg University, 55131 Mainz, Germany. Electronic address: oesch@uni-mainz.de.
Autoren
DOI
10.1016/j.phymed.2021.153476
eISSN
1618-095X
Externe Identifier
  • PubMed Identifier: 33593628
  • PubMed Central ID: PMC7840405
Open access
true
ISSN
0944-7113
Zeitschrift
Phytomedicine : international journal of phytotherapy and phytopharmacology
Schlüsselwörter
  • Animals
  • Humans
  • Plants, Medicinal
  • Drugs, Chinese Herbal
  • COVID-19
  • SARS-CoV-2
Sprache
eng
Medium
Print-Electronic
Online publication date
2021
Open access status
Open Access
Paginierung
153476
Datum der Veröffentlichung
2021
Status
Published
Datum der Datenerfassung
2021
Titel
Toxicity as prime selection criterion among SARS-active herbal medications.
Sub types
  • review-article
  • Review
  • Journal Article
Ausgabe der Zeitschrift
85

Files

https://europepmc.org/articles/PMC7840405?pdf=render

Data source: Europe PubMed Central

Abstract
We present here a new selection criterion for prioritizing research on efficacious drugs for the fight against COVID-19: the relative toxicity versus safety of herbal medications, which were effective against SARS in the 2002/2003 epidemic. We rank these medicines according to their toxicity versus safety as basis for preferential rapid research on their potential in the treatment of COVID-19. The data demonstrate that from toxicological information nothing speaks against immediate investigation on, followed by rapid implementation of Lonicera japonica, Morus alba, Forsythia suspensa, and Codonopsis spec. for treatment of COVID-19 patients. Glycyrrhiza spec. and Panax ginseng are ranked in second priority and ephedrine-free Herba Ephedrae extract in third priority (followed by several drugs in lower preferences). Rapid research on their efficacy in the therapy - as well as safety under the specific circumstances of COVID-19 - followed by equally rapid implementation will provide substantial advantages to Public Health including immediate availability, enlargement of medicinal possibilities, in cases where other means are not successful (non-responders), not tolerated (sensitive individuals) or just not available (as is presently the case) and thus minimize sufferings and save lives. Moreover, their moderate costs and convenient oral application are especially advantageous for underprivileged populations in developing countries.
Date of acceptance
2020
Autoren
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/33593628
DOI
10.1016/j.phymed.2021.153476
eISSN
1618-095X
Externe Identifier
  • PubMed Central ID: PMC7840405
Zeitschrift
Phytomedicine
Schlüsselwörter
  • COVID-19
  • Cytochrome P450, Phytochemicals
  • Public health
  • Rational phytotherapy
  • Toxicity
  • Animals
  • COVID-19
  • Drugs, Chinese Herbal
  • Humans
  • Plants, Medicinal
  • SARS-CoV-2
Sprache
eng
Country
Germany
Paginierung
153476
PII
S0944-7113(21)00018-0
Datum der Veröffentlichung
2021
Status
Published
Datum, an dem der Datensatz öffentlich gemacht wurde
2021
Titel
Toxicity as prime selection criterion among SARS-active herbal medications.
Sub types
  • Journal Article
  • Review
Ausgabe der Zeitschrift
85

Data source: PubMed

Beziehungen:
Property of

Tools